| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 56 | 2024 | 213 | 7.700 |
Why?
|
| Rhinitis | 46 | 2024 | 183 | 7.290 |
Why?
|
| Rhinitis, Allergic, Seasonal | 43 | 2017 | 179 | 4.890 |
Why?
|
| Rhinitis, Allergic, Perennial | 24 | 2023 | 81 | 3.150 |
Why?
|
| Tonsillectomy | 8 | 2023 | 31 | 3.120 |
Why?
|
| Nasal Polyps | 18 | 2023 | 64 | 3.010 |
Why?
|
| Nasal Mucosa | 44 | 2016 | 193 | 2.480 |
Why?
|
| Rhinitis, Allergic | 11 | 2024 | 52 | 2.430 |
Why?
|
| Nasal Provocation Tests | 36 | 2023 | 128 | 2.330 |
Why?
|
| Hypersensitivity | 19 | 2024 | 162 | 2.270 |
Why?
|
| Sleep Apnea, Obstructive | 8 | 2023 | 219 | 2.190 |
Why?
|
| Allergens | 30 | 2024 | 189 | 2.040 |
Why?
|
| Adenoidectomy | 9 | 2023 | 23 | 1.850 |
Why?
|
| Androstadienes | 9 | 2013 | 72 | 1.810 |
Why?
|
| Nose | 11 | 2022 | 95 | 1.550 |
Why?
|
| Anti-Allergic Agents | 13 | 2015 | 38 | 1.530 |
Why?
|
| Sleep Apnea, Central | 2 | 2022 | 16 | 1.420 |
Why?
|
| Chronic Disease | 32 | 2024 | 960 | 1.300 |
Why?
|
| Paranasal Sinuses | 13 | 2021 | 60 | 1.260 |
Why?
|
| Eosinophils | 18 | 2013 | 194 | 1.230 |
Why?
|
| Anti-Inflammatory Agents | 12 | 2016 | 353 | 1.120 |
Why?
|
| Maxillary Sinusitis | 4 | 2015 | 14 | 1.110 |
Why?
|
| Humans | 194 | 2024 | 93511 | 1.100 |
Why?
|
| Otolaryngology | 4 | 2023 | 55 | 1.030 |
Why?
|
| Acetates | 5 | 2010 | 60 | 1.020 |
Why?
|
| Quinolines | 5 | 2010 | 85 | 0.980 |
Why?
|
| Eye | 4 | 2013 | 109 | 0.980 |
Why?
|
| Nasal Cavity | 15 | 2014 | 91 | 0.930 |
Why?
|
| Endoscopy | 13 | 2022 | 366 | 0.910 |
Why?
|
| Administration, Intranasal | 26 | 2020 | 140 | 0.910 |
Why?
|
| Leukotriene Antagonists | 7 | 2015 | 24 | 0.900 |
Why?
|
| Double-Blind Method | 35 | 2016 | 1729 | 0.860 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2022 | 106 | 0.850 |
Why?
|
| Glucocorticoids | 6 | 2015 | 362 | 0.840 |
Why?
|
| Tracheotomy | 4 | 2020 | 18 | 0.810 |
Why?
|
| Loratadine | 7 | 2008 | 21 | 0.810 |
Why?
|
| Male | 105 | 2023 | 44553 | 0.810 |
Why?
|
| Histamine | 11 | 2013 | 116 | 0.780 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2023 | 289 | 0.780 |
Why?
|
| Ganglioneuroblastoma | 1 | 2023 | 4 | 0.780 |
Why?
|
| Female | 106 | 2023 | 48698 | 0.760 |
Why?
|
| Cross-Over Studies | 23 | 2016 | 390 | 0.740 |
Why?
|
| Histamine H1 Antagonists | 7 | 2002 | 39 | 0.740 |
Why?
|
| Child, Preschool | 23 | 2023 | 3829 | 0.710 |
Why?
|
| Adult | 84 | 2021 | 27918 | 0.690 |
Why?
|
| Child | 33 | 2024 | 7355 | 0.690 |
Why?
|
| Ambrosia | 5 | 2012 | 14 | 0.680 |
Why?
|
| Asthma | 13 | 2024 | 1039 | 0.680 |
Why?
|
| Terfenadine | 8 | 2004 | 23 | 0.660 |
Why?
|
| Polysomnography | 7 | 2019 | 153 | 0.610 |
Why?
|
| Histamine Release | 9 | 2008 | 53 | 0.590 |
Why?
|
| Quality of Life | 23 | 2023 | 1780 | 0.580 |
Why?
|
| Mouth Diseases | 1 | 2018 | 14 | 0.560 |
Why?
|
| Immunoglobulin E | 11 | 2018 | 148 | 0.560 |
Why?
|
| Maxillary Sinus | 3 | 2013 | 20 | 0.560 |
Why?
|
| Budesonide | 4 | 2014 | 46 | 0.560 |
Why?
|
| Choristoma | 1 | 2018 | 59 | 0.550 |
Why?
|
| Humidity | 15 | 2008 | 94 | 0.550 |
Why?
|
| Stomach | 1 | 2018 | 113 | 0.540 |
Why?
|
| Cysts | 1 | 2018 | 99 | 0.530 |
Why?
|
| Air | 8 | 2008 | 63 | 0.500 |
Why?
|
| Sneezing | 10 | 2011 | 36 | 0.500 |
Why?
|
| Methyl Ethers | 2 | 2013 | 34 | 0.490 |
Why?
|
| Anesthesia, Inhalation | 2 | 2013 | 37 | 0.490 |
Why?
|
| Anesthesia, Intravenous | 2 | 2013 | 36 | 0.490 |
Why?
|
| Methacholine Chloride | 10 | 2002 | 61 | 0.480 |
Why?
|
| Propofol | 2 | 2013 | 95 | 0.470 |
Why?
|
| Headache | 2 | 2015 | 75 | 0.470 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 131 | 0.460 |
Why?
|
| Nasal Decongestants | 4 | 2018 | 9 | 0.450 |
Why?
|
| Intestines | 1 | 2018 | 432 | 0.450 |
Why?
|
| Ephedrine | 2 | 2006 | 6 | 0.450 |
Why?
|
| Nasal Lavage Fluid | 10 | 2012 | 25 | 0.440 |
Why?
|
| Paranasal Sinus Diseases | 3 | 2013 | 19 | 0.440 |
Why?
|
| Device Removal | 1 | 2015 | 168 | 0.420 |
Why?
|
| Treatment Outcome | 21 | 2022 | 9098 | 0.420 |
Why?
|
| Anaphylaxis | 2 | 2024 | 30 | 0.410 |
Why?
|
| Personnel Selection | 1 | 2014 | 62 | 0.410 |
Why?
|
| Mycoses | 2 | 2014 | 44 | 0.410 |
Why?
|
| Osteogenesis, Distraction | 3 | 2020 | 29 | 0.410 |
Why?
|
| Reflex | 8 | 2013 | 80 | 0.400 |
Why?
|
| Nasal Obstruction | 4 | 2023 | 21 | 0.400 |
Why?
|
| Airway Obstruction | 4 | 2020 | 113 | 0.400 |
Why?
|
| Eosinophilia | 4 | 2017 | 87 | 0.400 |
Why?
|
| Internship and Residency | 3 | 2023 | 1090 | 0.400 |
Why?
|
| Beclomethasone | 5 | 1998 | 16 | 0.400 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 291 | 0.390 |
Why?
|
| Eye Diseases | 2 | 2011 | 58 | 0.390 |
Why?
|
| Dibenzoxepins | 1 | 2013 | 5 | 0.390 |
Why?
|
| Middle Aged | 43 | 2017 | 27569 | 0.390 |
Why?
|
| Oxymetazoline | 3 | 2011 | 9 | 0.370 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 425 | 0.370 |
Why?
|
| Mucociliary Clearance | 3 | 2007 | 7 | 0.370 |
Why?
|
| Adolescent | 27 | 2016 | 9606 | 0.360 |
Why?
|
| Abscess | 2 | 2015 | 94 | 0.360 |
Why?
|
| Desensitization, Immunologic | 7 | 2024 | 46 | 0.350 |
Why?
|
| Atropine | 5 | 1996 | 53 | 0.350 |
Why?
|
| Adenoids | 1 | 2011 | 10 | 0.350 |
Why?
|
| Mandible | 4 | 2020 | 126 | 0.340 |
Why?
|
| Vitamin D | 2 | 2010 | 272 | 0.330 |
Why?
|
| Ear Diseases | 1 | 2011 | 21 | 0.330 |
Why?
|
| Interleukins | 1 | 2011 | 133 | 0.330 |
Why?
|
| Gastroesophageal Reflux | 2 | 2016 | 121 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2018 | 2585 | 0.320 |
Why?
|
| Carbon Dioxide | 1 | 2011 | 203 | 0.320 |
Why?
|
| Steroids | 3 | 2022 | 168 | 0.320 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 3 | 2008 | 15 | 0.320 |
Why?
|
| Drug Therapy, Combination | 7 | 2018 | 759 | 0.310 |
Why?
|
| Respiratory Tract Diseases | 2 | 2001 | 45 | 0.310 |
Why?
|
| Postoperative Complications | 5 | 2019 | 2562 | 0.300 |
Why?
|
| Reflex, Abnormal | 1 | 2009 | 6 | 0.300 |
Why?
|
| Pierre Robin Syndrome | 2 | 2020 | 16 | 0.290 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1917 | 0.290 |
Why?
|
| Pollen | 7 | 2011 | 84 | 0.280 |
Why?
|
| Cytokines | 9 | 2022 | 863 | 0.280 |
Why?
|
| Job Application | 1 | 2008 | 18 | 0.280 |
Why?
|
| Lung Diseases | 1 | 2011 | 283 | 0.280 |
Why?
|
| Inhalation | 2 | 2010 | 34 | 0.280 |
Why?
|
| Biological Products | 3 | 2020 | 178 | 0.280 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2008 | 9 | 0.280 |
Why?
|
| Cervical Plexus | 1 | 2007 | 3 | 0.270 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2007 | 4 | 0.270 |
Why?
|
| Infant | 13 | 2021 | 3220 | 0.270 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2007 | 12 | 0.270 |
Why?
|
| Vagus Nerve | 1 | 2007 | 45 | 0.270 |
Why?
|
| Ipratropium | 5 | 2003 | 18 | 0.270 |
Why?
|
| Esophageal Diseases | 1 | 2007 | 25 | 0.270 |
Why?
|
| Staphylococcal Infections | 3 | 2008 | 286 | 0.270 |
Why?
|
| Neurilemmoma | 1 | 2007 | 37 | 0.260 |
Why?
|
| Pneumococcal Infections | 6 | 2008 | 46 | 0.260 |
Why?
|
| Evidence-Based Medicine | 5 | 2019 | 449 | 0.260 |
Why?
|
| Phthalazines | 3 | 2008 | 53 | 0.260 |
Why?
|
| Cyclopropanes | 5 | 2010 | 26 | 0.260 |
Why?
|
| Sulfides | 5 | 2010 | 68 | 0.250 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 31 | 0.250 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 300 | 0.250 |
Why?
|
| Antigens | 7 | 2001 | 224 | 0.240 |
Why?
|
| Mast Cells | 4 | 2012 | 96 | 0.240 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2006 | 31 | 0.240 |
Why?
|
| Comorbidity | 5 | 2016 | 1007 | 0.240 |
Why?
|
| Deglutition | 1 | 2006 | 85 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 1053 | 0.230 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2014 | 337 | 0.230 |
Why?
|
| Infant, Newborn | 8 | 2021 | 2479 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 3 | 1995 | 174 | 0.230 |
Why?
|
| Tracheal Neoplasms | 1 | 2005 | 7 | 0.230 |
Why?
|
| Retrospective Studies | 11 | 2021 | 10164 | 0.230 |
Why?
|
| Papilloma | 1 | 2005 | 23 | 0.230 |
Why?
|
| Hot Temperature | 7 | 2008 | 218 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 338 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 333 | 0.220 |
Why?
|
| Acute Disease | 6 | 2020 | 841 | 0.220 |
Why?
|
| Consensus | 4 | 2023 | 368 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 1 | 2005 | 89 | 0.220 |
Why?
|
| Patient Selection | 3 | 2020 | 690 | 0.210 |
Why?
|
| Statistics, Nonparametric | 6 | 2019 | 302 | 0.210 |
Why?
|
| Rhinitis, Vasomotor | 1 | 2024 | 1 | 0.210 |
Why?
|
| TRPV Cation Channels | 1 | 2024 | 16 | 0.210 |
Why?
|
| Prospective Studies | 11 | 2021 | 4560 | 0.200 |
Why?
|
| Parotitis | 1 | 2003 | 6 | 0.200 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 284 | 0.200 |
Why?
|
| Surveys and Questionnaires | 9 | 2016 | 2802 | 0.200 |
Why?
|
| Bacterial Infections | 2 | 2014 | 179 | 0.200 |
Why?
|
| Temperature | 5 | 2007 | 424 | 0.200 |
Why?
|
| Iron-Dextran Complex | 1 | 2023 | 1 | 0.200 |
Why?
|
| Women | 1 | 2023 | 26 | 0.200 |
Why?
|
| Papillomaviridae | 2 | 2005 | 179 | 0.190 |
Why?
|
| Fluticasone | 5 | 2010 | 31 | 0.190 |
Why?
|
| Pharynx | 1 | 2023 | 44 | 0.190 |
Why?
|
| Nasal Lavage | 1 | 2022 | 2 | 0.190 |
Why?
|
| Poaceae | 5 | 2011 | 18 | 0.190 |
Why?
|
| Symptom Assessment | 2 | 2020 | 71 | 0.190 |
Why?
|
| Neurogenic Inflammation | 1 | 2002 | 3 | 0.190 |
Why?
|
| Cilia | 2 | 2016 | 29 | 0.190 |
Why?
|
| Dermatitis, Atopic | 1 | 2003 | 65 | 0.180 |
Why?
|
| Serine Endopeptidases | 1 | 2002 | 148 | 0.180 |
Why?
|
| Encephalocele | 1 | 2022 | 23 | 0.180 |
Why?
|
| Tongue | 2 | 2016 | 58 | 0.180 |
Why?
|
| Microbiota | 3 | 2018 | 425 | 0.180 |
Why?
|
| Atmosphere Exposure Chambers | 2 | 2001 | 7 | 0.170 |
Why?
|
| Young Adult | 7 | 2015 | 6930 | 0.170 |
Why?
|
| Speech | 1 | 2021 | 90 | 0.160 |
Why?
|
| Bronchial Provocation Tests | 1 | 2000 | 24 | 0.160 |
Why?
|
| Research | 1 | 2001 | 251 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 283 | 0.160 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1723 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 110 | 0.160 |
Why?
|
| Streptococcal Infections | 2 | 2015 | 56 | 0.150 |
Why?
|
| Lymphangioma | 1 | 1999 | 15 | 0.150 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 43 | 0.150 |
Why?
|
| Pregnadienediols | 3 | 2011 | 13 | 0.150 |
Why?
|
| Bevacizumab | 1 | 2021 | 256 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 57 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 327 | 0.150 |
Why?
|
| Child Development | 1 | 2021 | 166 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2021 | 917 | 0.150 |
Why?
|
| Skin Tests | 3 | 2018 | 46 | 0.150 |
Why?
|
| Capillary Permeability | 3 | 2013 | 131 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2020 | 137 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2005 | 1914 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 130 | 0.140 |
Why?
|
| Goals | 1 | 2019 | 67 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 291 | 0.140 |
Why?
|
| Inflammation Mediators | 4 | 2003 | 159 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 163 | 0.140 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 22 | 0.140 |
Why?
|
| Leukocyte Count | 4 | 2012 | 210 | 0.140 |
Why?
|
| Pulmonary Ventilation | 2 | 2011 | 32 | 0.140 |
Why?
|
| Serum Albumin | 5 | 2002 | 124 | 0.140 |
Why?
|
| Placebos | 4 | 2008 | 206 | 0.140 |
Why?
|
| Albumins | 3 | 2008 | 123 | 0.140 |
Why?
|
| Complementary Therapies | 2 | 2018 | 53 | 0.140 |
Why?
|
| Mucous Membrane | 4 | 2008 | 82 | 0.140 |
Why?
|
| Biological Therapy | 1 | 2018 | 46 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 5 | 2006 | 51 | 0.140 |
Why?
|
| Analysis of Variance | 8 | 2006 | 884 | 0.140 |
Why?
|
| Olfactory Mucosa | 2 | 2010 | 33 | 0.140 |
Why?
|
| Esophagus | 2 | 2009 | 113 | 0.130 |
Why?
|
| Dilatation | 1 | 2018 | 47 | 0.130 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 202 | 0.130 |
Why?
|
| Clemastine | 1 | 1997 | 2 | 0.130 |
Why?
|
| Pandemics | 2 | 2020 | 873 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 608 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2018 | 176 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 3910 | 0.130 |
Why?
|
| Allergists | 1 | 2016 | 5 | 0.130 |
Why?
|
| Prostaglandin D2 | 2 | 1996 | 28 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 2013 | 43 | 0.130 |
Why?
|
| Medical History Taking | 2 | 2013 | 82 | 0.130 |
Why?
|
| Cholinergic Antagonists | 2 | 2003 | 30 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 73 | 0.120 |
Why?
|
| Animals | 14 | 2016 | 28155 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 39 | 0.120 |
Why?
|
| Delphi Technique | 3 | 2023 | 135 | 0.120 |
Why?
|
| Leukotriene B4 | 1 | 1996 | 16 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 3 | 2014 | 836 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 64 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 1998 | 58 | 0.120 |
Why?
|
| Respiratory Hypersensitivity | 2 | 1999 | 36 | 0.120 |
Why?
|
| Eikenella corrodens | 1 | 2015 | 1 | 0.120 |
Why?
|
| Trismus | 1 | 2015 | 6 | 0.120 |
Why?
|
| Hypesthesia | 1 | 2015 | 14 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2015 | 15 | 0.120 |
Why?
|
| Inflammation | 7 | 2015 | 1050 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2006 | 2495 | 0.120 |
Why?
|
| Cellulose | 1 | 2016 | 59 | 0.120 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2015 | 22 | 0.120 |
Why?
|
| Tachycardia | 1 | 2015 | 38 | 0.120 |
Why?
|
| Immunotherapy | 3 | 2024 | 761 | 0.120 |
Why?
|
| Muscarinic Antagonists | 1 | 1996 | 59 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2018 | 406 | 0.120 |
Why?
|
| Pharyngeal Diseases | 1 | 2015 | 10 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2016 | 87 | 0.110 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 6 | 0.110 |
Why?
|
| Eustachian Tube | 1 | 2015 | 9 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2006 | 657 | 0.110 |
Why?
|
| Respiratory System | 2 | 2011 | 117 | 0.110 |
Why?
|
| Risk Factors | 5 | 2020 | 5898 | 0.110 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 26 | 0.110 |
Why?
|
| Polyps | 1 | 2015 | 26 | 0.110 |
Why?
|
| Premedication | 2 | 1994 | 57 | 0.110 |
Why?
|
| Airway Management | 1 | 2015 | 48 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1931 | 0.110 |
Why?
|
| Fever | 1 | 2015 | 122 | 0.110 |
Why?
|
| Decision Making | 1 | 2020 | 674 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2016 | 189 | 0.110 |
Why?
|
| Radiography | 2 | 2014 | 790 | 0.110 |
Why?
|
| Ancillary Services, Hospital | 1 | 2014 | 1 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2013 | 2440 | 0.110 |
Why?
|
| Oxygen | 1 | 2019 | 769 | 0.110 |
Why?
|
| Biomarkers | 3 | 2017 | 1910 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 116 | 0.110 |
Why?
|
| Body Temperature | 3 | 2005 | 131 | 0.110 |
Why?
|
| Phenotype | 3 | 2020 | 2544 | 0.100 |
Why?
|
| Rhinometry, Acoustic | 1 | 2014 | 3 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 255 | 0.100 |
Why?
|
| United States | 7 | 2023 | 7619 | 0.100 |
Why?
|
| Smoking | 2 | 2016 | 648 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 242 | 0.100 |
Why?
|
| Reference Values | 2 | 2013 | 608 | 0.100 |
Why?
|
| Antigens, Fungal | 1 | 2013 | 6 | 0.100 |
Why?
|
| Foreign Bodies | 2 | 2009 | 63 | 0.100 |
Why?
|
| Otitis Media | 2 | 2003 | 20 | 0.100 |
Why?
|
| Anesthetics, Intravenous | 1 | 2013 | 43 | 0.100 |
Why?
|
| Injections, Intraocular | 1 | 2013 | 5 | 0.100 |
Why?
|
| Olopatadine Hydrochloride | 1 | 2013 | 6 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 233 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2365 | 0.090 |
Why?
|
| Fungi | 1 | 2013 | 67 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1799 | 0.090 |
Why?
|
| Phleum | 1 | 2012 | 2 | 0.090 |
Why?
|
| Operative Time | 1 | 2013 | 167 | 0.090 |
Why?
|
| Mites | 1 | 2012 | 17 | 0.090 |
Why?
|
| Cost of Illness | 3 | 2015 | 159 | 0.090 |
Why?
|
| Immune System | 1 | 1993 | 101 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 122 | 0.090 |
Why?
|
| Anesthetics, Inhalation | 1 | 2013 | 102 | 0.090 |
Why?
|
| Dust | 1 | 2012 | 26 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1847 | 0.090 |
Why?
|
| Skin Temperature | 2 | 2003 | 16 | 0.090 |
Why?
|
| Bronchi | 3 | 2012 | 225 | 0.090 |
Why?
|
| Neck | 2 | 2006 | 98 | 0.090 |
Why?
|
| Tumor Necrosis Factors | 1 | 2011 | 14 | 0.090 |
Why?
|
| Ovalbumin | 3 | 2006 | 102 | 0.090 |
Why?
|
| Bodily Secretions | 1 | 2011 | 3 | 0.090 |
Why?
|
| Epigenomics | 1 | 2012 | 109 | 0.090 |
Why?
|
| Antigens, Plant | 1 | 2011 | 15 | 0.090 |
Why?
|
| Ioxaglic Acid | 1 | 2011 | 6 | 0.090 |
Why?
|
| Time Factors | 8 | 2006 | 5410 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 624 | 0.090 |
Why?
|
| Airway Resistance | 5 | 1999 | 68 | 0.080 |
Why?
|
| Ribonucleases | 2 | 2001 | 92 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2011 | 158 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 287 | 0.080 |
Why?
|
| Hydroxyapatites | 1 | 2010 | 7 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 394 | 0.080 |
Why?
|
| Molar | 1 | 2010 | 21 | 0.080 |
Why?
|
| Oral Surgical Procedures | 1 | 2010 | 19 | 0.080 |
Why?
|
| Colony Count, Microbial | 2 | 2008 | 40 | 0.080 |
Why?
|
| Probability | 2 | 2008 | 355 | 0.080 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 23 | 0.080 |
Why?
|
| Biopsy | 3 | 1999 | 1175 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 1001 | 0.080 |
Why?
|
| Algorithms | 3 | 2015 | 1953 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2007 | 1448 | 0.080 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 49 | 0.080 |
Why?
|
| Deafness | 1 | 2009 | 47 | 0.080 |
Why?
|
| Cochlear Implantation | 1 | 2009 | 34 | 0.080 |
Why?
|
| Neutrophils | 5 | 2001 | 324 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1906 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 347 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 40 | 0.070 |
Why?
|
| Flow Cytometry | 4 | 2014 | 712 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 512 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1103 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.070 |
Why?
|
| Fundoplication | 1 | 2009 | 73 | 0.070 |
Why?
|
| Urban Health | 1 | 2008 | 55 | 0.070 |
Why?
|
| Aged | 10 | 2016 | 20430 | 0.070 |
Why?
|
| Turbinates | 3 | 2015 | 11 | 0.070 |
Why?
|
| Phenoxybenzamine | 2 | 2005 | 15 | 0.070 |
Why?
|
| Eyebrows | 1 | 2008 | 10 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1161 | 0.070 |
Why?
|
| Epidural Abscess | 1 | 2008 | 5 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2005 | 30 | 0.070 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 24 | 0.070 |
Why?
|
| Lacrimal Apparatus | 1 | 2008 | 11 | 0.070 |
Why?
|
| Foot | 3 | 2003 | 56 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 756 | 0.070 |
Why?
|
| Intermediate Filament Proteins | 1 | 2008 | 35 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1546 | 0.070 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 54 | 0.070 |
Why?
|
| Orbit | 1 | 2008 | 38 | 0.070 |
Why?
|
| Vocal Cord Paralysis | 1 | 2007 | 25 | 0.070 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 71 | 0.070 |
Why?
|
| Craniotomy | 1 | 2008 | 91 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 87 | 0.060 |
Why?
|
| Parasympathetic Nervous System | 3 | 2001 | 33 | 0.060 |
Why?
|
| Receptors, Histamine H1 | 2 | 2000 | 8 | 0.060 |
Why?
|
| Urban Population | 1 | 2008 | 234 | 0.060 |
Why?
|
| Kartagener Syndrome | 1 | 2007 | 1 | 0.060 |
Why?
|
| Histamine Antagonists | 2 | 2018 | 14 | 0.060 |
Why?
|
| Hypopharynx | 1 | 2006 | 9 | 0.060 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2006 | 84 | 0.060 |
Why?
|
| Videotape Recording | 1 | 2006 | 49 | 0.060 |
Why?
|
| Incidence | 1 | 2011 | 1701 | 0.060 |
Why?
|
| Mice | 8 | 2008 | 12269 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2008 | 312 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2006 | 129 | 0.060 |
Why?
|
| Muscarinic Agonists | 2 | 1996 | 22 | 0.060 |
Why?
|
| Sensation | 1 | 2006 | 48 | 0.060 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 23 | 0.060 |
Why?
|
| Water | 2 | 2005 | 307 | 0.060 |
Why?
|
| Disease Management | 2 | 2020 | 358 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2008 | 247 | 0.060 |
Why?
|
| Head | 1 | 2006 | 131 | 0.060 |
Why?
|
| Nasal Surgical Procedures | 2 | 2016 | 9 | 0.060 |
Why?
|
| E-Selectin | 2 | 1996 | 31 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2006 | 84 | 0.060 |
Why?
|
| Prevalence | 3 | 2020 | 1321 | 0.060 |
Why?
|
| Cystic Fibrosis | 3 | 1995 | 119 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2009 | 3828 | 0.060 |
Why?
|
| Physical Examination | 2 | 2018 | 144 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1713 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2021 | 159 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 126 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 295 | 0.050 |
Why?
|
| Mometasone Furoate | 3 | 2011 | 19 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2020 | 375 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1395 | 0.050 |
Why?
|
| Therapeutic Irrigation | 2 | 2002 | 75 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1985 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 492 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 486 | 0.050 |
Why?
|
| Kinetics | 2 | 1999 | 1492 | 0.050 |
Why?
|
| Basophils | 2 | 1994 | 26 | 0.050 |
Why?
|
| Suppuration | 1 | 2003 | 8 | 0.050 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 67 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2005 | 175 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2008 | 80 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2012 | 700 | 0.050 |
Why?
|
| Tryptases | 1 | 2002 | 11 | 0.050 |
Why?
|
| Cell Separation | 2 | 2014 | 200 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2003 | 65 | 0.050 |
Why?
|
| Pruritus | 1 | 2002 | 30 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 189 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2023 | 64 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2391 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 484 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2022 | 131 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 1275 | 0.050 |
Why?
|
| Climate Change | 1 | 2023 | 61 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2023 | 131 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2006 | 1006 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2002 | 307 | 0.040 |
Why?
|
| Supine Position | 1 | 2001 | 34 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 7061 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 422 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 624 | 0.040 |
Why?
|
| Neuropeptides | 2 | 1999 | 114 | 0.040 |
Why?
|
| Skull Base | 1 | 2022 | 50 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2006 | 2121 | 0.040 |
Why?
|
| Respiratory Mucosa | 2 | 2018 | 90 | 0.040 |
Why?
|
| Lidocaine | 3 | 2003 | 62 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 30 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2001 | 89 | 0.040 |
Why?
|
| Neurosurgery | 1 | 2023 | 141 | 0.040 |
Why?
|
| Receptors, Muscarinic | 1 | 2001 | 42 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2001 | 36 | 0.040 |
Why?
|
| Hearing | 1 | 2021 | 62 | 0.040 |
Why?
|
| Antibody Specificity | 2 | 1997 | 126 | 0.040 |
Why?
|
| Internationality | 1 | 2021 | 77 | 0.040 |
Why?
|
| Workload | 1 | 2001 | 126 | 0.040 |
Why?
|
| General Surgery | 1 | 2023 | 248 | 0.040 |
Why?
|
| Body Temperature Regulation | 1 | 2000 | 59 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2000 | 18 | 0.040 |
Why?
|
| Atrophy | 1 | 2001 | 128 | 0.040 |
Why?
|
| Educational Status | 1 | 2021 | 197 | 0.040 |
Why?
|
| Reaction Time | 1 | 2001 | 317 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2715 | 0.040 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 70 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 33 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 37 | 0.040 |
Why?
|
| Masks | 1 | 2000 | 31 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1922 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 55 | 0.040 |
Why?
|
| Nose Neoplasms | 1 | 1999 | 36 | 0.040 |
Why?
|
| Antibody Formation | 3 | 1997 | 169 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2001 | 187 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 220 | 0.040 |
Why?
|
| Checklist | 1 | 2020 | 73 | 0.040 |
Why?
|
| Capsaicin | 2 | 1999 | 43 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2000 | 112 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 155 | 0.040 |
Why?
|
| Leukocytes | 2 | 2001 | 210 | 0.040 |
Why?
|
| Parents | 1 | 2021 | 292 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1998 | 68 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1998 | 39 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 60 | 0.030 |
Why?
|
| Immunization | 1 | 1998 | 154 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 2018 | 53 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 775 | 0.030 |
Why?
|
| Recurrence | 2 | 2018 | 1190 | 0.030 |
Why?
|
| Tachyphylaxis | 2 | 1994 | 14 | 0.030 |
Why?
|
| Epithelium | 1 | 1998 | 316 | 0.030 |
Why?
|
| Patient Participation | 1 | 2019 | 229 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 137 | 0.030 |
Why?
|
| Peroxidases | 1 | 1997 | 34 | 0.030 |
Why?
|
| Respiratory Therapy | 1 | 1997 | 17 | 0.030 |
Why?
|
| Th2 Cells | 2 | 2012 | 149 | 0.030 |
Why?
|
| Respiration | 2 | 2000 | 269 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 1996 | 18 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 423 | 0.030 |
Why?
|
| Albuterol | 1 | 1997 | 35 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 1996 | 15 | 0.030 |
Why?
|
| Otolaryngologists | 1 | 2016 | 5 | 0.030 |
Why?
|
| Probiotics | 1 | 2018 | 92 | 0.030 |
Why?
|
| Allergy and Immunology | 1 | 2016 | 16 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2006 | 1101 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 69 | 0.030 |
Why?
|
| Nasal Sprays | 1 | 2016 | 9 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 660 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 1996 | 98 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1997 | 203 | 0.030 |
Why?
|
| Prostaglandins | 1 | 1996 | 44 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 225 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 657 | 0.030 |
Why?
|
| Mandibular Advancement | 1 | 2016 | 6 | 0.030 |
Why?
|
| Oropharynx | 1 | 2016 | 14 | 0.030 |
Why?
|
| Sphenoid Sinus | 1 | 1995 | 8 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 30 | 0.030 |
Why?
|
| Internal Fixators | 1 | 2016 | 29 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 87 | 0.030 |
Why?
|
| Peptide Hydrolases | 2 | 1992 | 99 | 0.030 |
Why?
|
| Trachea | 1 | 1996 | 245 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 2 | 1994 | 62 | 0.030 |
Why?
|
| Acupuncture Therapy | 1 | 2015 | 9 | 0.030 |
Why?
|
| Models, Biological | 2 | 2008 | 1768 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2018 | 355 | 0.030 |
Why?
|
| Physician's Role | 1 | 2016 | 176 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 1996 | 159 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 293 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1994 | 76 | 0.030 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1994 | 7 | 0.030 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 41 | 0.030 |
Why?
|
| Mucocele | 1 | 1994 | 5 | 0.030 |
Why?
|
| Face | 1 | 1995 | 109 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 91 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1994 | 134 | 0.030 |
Why?
|
| Cell Movement | 1 | 1998 | 809 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 133 | 0.030 |
Why?
|
| Mucus | 1 | 1994 | 19 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 52 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 1994 | 53 | 0.030 |
Why?
|
| Triamcinolone Acetonide | 1 | 1993 | 8 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 137 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2004 | 163 | 0.030 |
Why?
|
| Patient Care | 2 | 2004 | 97 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 920 | 0.030 |
Why?
|
| Cold Temperature | 1 | 1993 | 159 | 0.020 |
Why?
|
| Diphenhydramine | 1 | 1993 | 14 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 1993 | 75 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 174 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 1995 | 246 | 0.020 |
Why?
|
| Linear Models | 1 | 1994 | 413 | 0.020 |
Why?
|
| Paper | 1 | 1992 | 11 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 306 | 0.020 |
Why?
|
| Filtration | 1 | 1992 | 27 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 621 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Administration, Sublingual | 1 | 2012 | 5 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1992 | 109 | 0.020 |
Why?
|
| Immersion | 2 | 2003 | 22 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1996 | 660 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2012 | 71 | 0.020 |
Why?
|
| Up-Regulation | 1 | 1994 | 730 | 0.020 |
Why?
|
| Pediatrics | 1 | 2016 | 385 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2008 | 3435 | 0.020 |
Why?
|
| Hypersensitivity, Immediate | 1 | 1992 | 64 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 1118 | 0.020 |
Why?
|
| Leukotrienes | 1 | 1991 | 20 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 617 | 0.020 |
Why?
|
| Eosinophil Granule Proteins | 2 | 2001 | 19 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 337 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 110 | 0.020 |
Why?
|
| Omalizumab | 1 | 2010 | 8 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 476 | 0.020 |
Why?
|
| Agnosia | 1 | 2010 | 6 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 46 | 0.020 |
Why?
|
| Blood Proteins | 2 | 2001 | 145 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 21 | 0.020 |
Why?
|
| Alveolar Bone Loss | 1 | 2010 | 20 | 0.020 |
Why?
|
| Bacteria | 1 | 2014 | 509 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 101 | 0.020 |
Why?
|
| Hydroxyzine | 1 | 1989 | 7 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1989 | 15 | 0.020 |
Why?
|
| Cetirizine | 1 | 1989 | 12 | 0.020 |
Why?
|
| Audiology | 1 | 2009 | 2 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2010 | 99 | 0.020 |
Why?
|
| Language Development Disorders | 1 | 2009 | 24 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 1989 | 45 | 0.020 |
Why?
|
| Education | 1 | 2009 | 59 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2009 | 58 | 0.020 |
Why?
|
| Calcium Channels | 1 | 1989 | 180 | 0.020 |
Why?
|
| Serotonin | 1 | 1989 | 209 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 342 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2009 | 91 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 985 | 0.020 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2008 | 4 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 370 | 0.020 |
Why?
|
| Dopamine | 1 | 1989 | 276 | 0.020 |
Why?
|
| Pneumocephalus | 1 | 2008 | 12 | 0.020 |
Why?
|
| Frontal Sinus | 1 | 2008 | 7 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2009 | 237 | 0.020 |
Why?
|
| Esophagitis | 1 | 2008 | 40 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 80 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2850 | 0.020 |
Why?
|
| Random Allocation | 2 | 2001 | 307 | 0.020 |
Why?
|
| Drainage | 1 | 2008 | 170 | 0.020 |
Why?
|
| Lactoferrin | 2 | 1997 | 10 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 481 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2005 | 35 | 0.010 |
Why?
|
| Skin | 1 | 2008 | 578 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2006 | 373 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 108 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 829 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2006 | 276 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 570 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 186 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 99 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 83 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Chemokine CCL11 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Air Conditioning | 1 | 2001 | 6 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 32 | 0.010 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2001 | 13 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 141 | 0.010 |
Why?
|
| Acoustics | 1 | 2001 | 46 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2001 | 167 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2001 | 139 | 0.010 |
Why?
|
| Neurokinin A | 1 | 1999 | 12 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1999 | 39 | 0.010 |
Why?
|
| Substance P | 1 | 1999 | 62 | 0.010 |
Why?
|
| Nasopharynx | 1 | 1999 | 51 | 0.010 |
Why?
|
| Hospitalization | 1 | 2004 | 937 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1997 | 14 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 38 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1997 | 102 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1996 | 125 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 93 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2464 | 0.010 |
Why?
|
| Calcium | 1 | 2001 | 1176 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 4272 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 1996 | 117 | 0.010 |
Why?
|
| Jaw Neoplasms | 1 | 1995 | 6 | 0.010 |
Why?
|
| Facial Neoplasms | 1 | 1995 | 26 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1995 | 47 | 0.010 |
Why?
|
| Soft Tissue Infections | 1 | 1995 | 27 | 0.010 |
Why?
|
| Tears | 1 | 1994 | 8 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 2026 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1995 | 225 | 0.010 |
Why?
|
| Anesthesia | 1 | 1996 | 175 | 0.010 |
Why?
|
| Tosylarginine Methyl Ester | 1 | 1994 | 5 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1994 | 41 | 0.010 |
Why?
|
| Acute-Phase Reaction | 1 | 1994 | 16 | 0.010 |
Why?
|
| Phospholipases A | 1 | 1994 | 45 | 0.010 |
Why?
|
| Radioallergosorbent Test | 1 | 1993 | 8 | 0.010 |
Why?
|
| Frontal Sinusitis | 1 | 1993 | 2 | 0.010 |
Why?
|
| Sphenoid Sinusitis | 1 | 1993 | 2 | 0.010 |
Why?
|
| Ethmoid Sinusitis | 1 | 1993 | 4 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 1993 | 29 | 0.010 |
Why?
|
| Cephalometry | 1 | 1993 | 47 | 0.010 |
Why?
|
| Tuberculosis | 1 | 1995 | 124 | 0.010 |
Why?
|
| Nasal Septum | 1 | 1993 | 27 | 0.010 |
Why?
|
| Seasons | 1 | 1993 | 240 | 0.010 |
Why?
|
| Kinins | 1 | 1992 | 31 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 803 | 0.000 |
Why?
|